Endoscopic cryo-ablation company CSA Medical said today it won expanded FDA 510(k) clearance for its TruFreeze spray cryotherapy system, now cleared for use on patients with Barrett’s esophagus with low grade dysplasia.
With the clearance, the device is now approved for both low and high grade dysplasia as well as malignancies, the Boston-based company said.
“Over the past few years, studies have underscored the potential risk for Barrett’s esophagus with low grade dysplasia to progress to esophageal adenocarcinoma. Intervening at this level of dysplasia has become common practice and is recognized in our society guidelines.  My colleagues and I have used liquid nitrogen spray cryotherapy for over a decade to treat Barrett’s esophagus with high levels of efficacy and patient tolerability.  With approval of this expanded label, the FDA has recognized spray cryotherapy’s ability to positively impact the lives of our Barrett’s patients,” Dr. Michael Smith of New York’s Mount Sinai hospitals said in a press release.
The TruFreeze system is designed as a cryosurgical tool designed for use in dermatology, gynecology, general surgery and to ablate benign and malignant lesions.
The company touts the TruFreeze device as the only ablation technology designed to ablate Barrett’s Esophagus with a high grade dysplasia or cancers as such as in the esophagus with a non-contact liquid nitrogen spray cryotherapy sy…

Source: Mass DeviceCategory: Medical Devices Authors: Tags: 510(k) Food & Drug Administration (FDA) Otolaryngology Ear, Nose & Throat Regulatory/Compliance CSA Medical Inc. Source Type: news

Related Links:

Publication date: Available online 7 July 2018Source: European Journal of Surgical OncologyAuthor(s): Leila Sisic, Thomas Schmidt, Susanne Blank, Henrik Nienhueser, Sara Dorr, Georg Martin Haag, Dirk Jäger, Thomas Bruckner, Beat P. Müller-Stich, Katja Ott, Markus W. Büchler, Alexis UlrichAbstractBackgroundPrognostic differences between pTN- and ypTN-categories and the prognostic accuracy of the 8th edition UICC-pTNM- and AJCC-ypTNM-staging-system for esophageal and gastric adenocarcinoma are unclear.MethodsWe retrospectively analyzed data of 740 patients with esophagogastric adenocarcinoma, who underwent cur…

ConclusionsBarrett’s esophagus, which has a heterogeneous epithelium, might yield different diagnosis based on endoscopic evaluation and immunohistological investigation. Thus, the use of MUC1, p27, and CK7 might strengthen the truthful diagnosis. MUC-1, CK7, and c-p27 immunostaining can be used as the predictive markers for esophageal cancer progression from Barrett’s esophagus.

ConclusionsPatients with locally-advanced oesophageal carcinoma, who responded to trimodality therapy with a pCR, could be achieved a 10-year survival rate of 51%.

ConclusionOur data underscore the importance of tumor size as a predictor for upstaging and of completing a thorough lymph node dissection for staging purposes.

Publication date: October 2017Source: Best Practice &Research Clinical Gastroenterology, Volume 31, Issue 5Author(s): Jing Dong, Aaron P. ThriftAbstractOesophago-gastric cancers (oesophageal and gastric cancers) are common, highly fatal cancers. Oesophageal squamous cell carcinoma (OSCC) and oesophageal adenocarcinoma (OAC) are the two main histological subtypes of oesophageal cancer. Globally, OSCC remains the most common histological subtype of oesophageal cancer, with the highest burden occurring along two geographic belts, one from north central China through the central Asian republics to northern Iran, and one fr…

Publication date: 5 June 2018Source: Stem Cell Reports, Volume 10, Issue 6Author(s): Véronique Giroux, Julien Stephan, Priya Chatterji, Ben Rhoades, E. Paul Wileyto, Andres J. Klein-Szanto, Christopher J. Lengner, Kathryn E. Hamilton, Anil K. RustgiSummaryTwo principal stem cell pools orchestrate the rapid cell turnover in the intestinal epithelium. Rapidly cycling Lgr5+ stem cells are intercalated between the Paneth cells at the crypt base (CBCs) and injury-resistant reserve stem cells reside above the crypt base. The intermediate filament Keratin 15 (Krt15) marks either stem cells or long-lived progenitor cells th…

Publication date: September 2018Source: Clinica Chimica Acta, Volume 484Author(s): Song Mao, Xiaopeng Wang, Liangxia Wu, Dou Zang, Wenjing ShiAbstractBackgroundWe assessed the association between tissue klotho protein expression and the risk and progression of malignancies.MethodsWe searched the electronic databases for the studies regarding the relationship between tissue klotho protein expression and risk/progression of malignancies through January 2018. We calculated the pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) to evaluate the impact of tissue klotho protein expression on malignancies. A…

AbstractPurposeTherapeutic decisions in esophageal adenocarcinomas (EAC) restricted to mucosa (pT1a) or submucosa (pT1b) depend mainly on classic histomorphology-based criteria like tumor grading or lymphovascular invasion with limited success. There is a strong need for reliable pre-therapeutical biomarker-based evaluation also applicable on endoscopically obtained biopsies.MethodsPatients who underwent esophagectomy due to EAC in a high volume center between 1999 and 2016 were included. Tissue microarrays (TMA) were retrospectively established from the formalin-fixed and paraffin-embedded material of the resected specime…

Esophageal adenocarcinoma (EAC) is the sixth leading cause of cancer deaths worldwide and dramatically increasing in incidence over the last decade. Gastroesophageal reflux and Barret ’s esophagus are well-established risk factors for disease progression. Conjugated bile acids (CBAs), including taurocholate (TCA), represent the major bile acids in the gastroesophageal refluxate of advanced Barret’s esophagus and EAC patients. Our previous studies suggested that CBA-induced ac tivation of sphingosine 1-phosphate receptor 2 (S1PR2) plays a critical role in promoting cholangiocarcinoma cell invasive growth.

Source: American Journal of PathologyCategory: Pathology Authors: Tags: Regular Article Source Type: research

In this study, we examined centrosomes in Barrett’s esophagus tumorigenesis, a well-characterized multistep pathway of progression, from the premalignant condition to the metastatic disease. This human cancer model allows the study of sequential steps of progression within the same patient and has representative cell lines from all stages of disease. Remarkably, centrosome amplification was detected as early as the premalignant condition and was significantly expanded in dysplasia. It was then present throughout malignant transformation both in adenocarcinoma and metastasis. The early expansion of centrosome amplific…

Source: Journal of Cell BiologyCategory: Cytology Authors: Tags: Organelles, Cancer Reports Source Type: research





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here